The companies will lay emphasis on developing and commercializing three drug candidates, including two of Miragen’s programs (miR-208 and miR-15/195) and one additional target which is to be identified.
Miragen will receive up to $45m in total upfront, research support and near-term milestone payments over the next three years.
Additional clinical and commercial milestones for the development of the three compounds, would value the deal at around $1bn.
This agreement is said to provide worldwide rights to Servier, excluding the US and Japan.